Navigation Links
New analysis shows liver cancer incidence has tripled since 1970s, but survival rates improving
Date:2/18/2009

Study Summary

A new study examining data on incidence trends, mortality rates and survival rates from the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) cancer registries indicates that the incidence of liver cancer in the United States tripled between 1975 and 2005.

Researchers also found for the first time that one- through five-year survival rates improved significantly for patients diagnosed with liver cancer between 1992 and 2005, in part because more patients were diagnosed at earlier stages, when treatment is more effective. Earlier diagnosis may be due to increasing awareness and screening to detect localized disease in patients at risk for liver cancer.

"Although the study could not determine why liver incidence rates are increasing, these trends may be partially attributable to an increase in chronic hepatitis C, which together with hepatitis B is a major risk factor for liver cancer," said Dr. Sean Altekruse, an Epidemiologist with the NCI's SEER Program and the study's lead author. "Additional research into the factors related to this increase in incidence will be vital to preventing these rates from rising further." Dr. Altekruse noted that heavy alcohol consumption, fatty liver disease, obesity, diabetes mellitus and iron storage diseases may also contribute to the increasing incidence of liver cancer.

The study found that between 1975 and 2005, liver cancer rates tripled, from 1.6 cases per 100,000 people to 4.9 per 100,000. From 1992 to 2005, liver cancer incidence trends increased significantly:

  • African-Americans and Hispanics both experienced an approximately 67 percent increase in liver cancer incidence between 1992 and 2005 (4.2 to 7.0/100,000 and 4.8 to 8.0/100,000, respectively), and whites experienced an approximately 50 percent increase in incidence (2.6 to 3.9/100,000) during this time period.

  • Between 2000 and 2005, incidence rates increased most markedly among African-American men (42 percent, 28.7 to 40.8/100,000), Hispanic men (43 percent, 23 to 32.8/100,000), and white men (43 percent, (11.5 to 16.5/100,000) 50 to 59 years of age. These increases may be partially due to an epidemic of hepatitis C infection that began in the 1960s, when men in this age range were young adults.

  • From 1992 to 2005, liver cancer incidence rates among Asians and Pacific Islanders were the highest of all racial groups overall; however, rates increased by a relatively modest 17 percent (10.0 to 11.7/100,000) in this time period. Researchers attribute a substantial portion of liver cancer cases in Asians and Pacific Islanders to higher rates of hepatitis B among some Asian subgroups.

One-year survival rates nearly doubled between 1992 and 2005, rising from 25 percent of patients to 47 percent. Dr. Altekruse points out that while the increasing survival rates are encouraging, further improvement is still needed, noting that one-year survival rates are still below 50 percent.

ASCO Perspective
Jennifer Obel, ASCO official and Attending Physician, NorthShore University HealthSystem

"Early screening for patients with hepatitis C, a leading risk factor for liver cancer, has directly contributed to increasing survival rates for patients living with liver cancer. When detected early, there are significantly more treatment options for liver cancer in most cases, the earlier it is caught, the better the prognosis. This study points to the need to identify even more at-risk individuals through early screening programs to improve prognosis with potentially curative therapy."


'/>"/>

Contact: Kelly Powell
kelly.powell@asco.org
571-483-1365
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. Study, meta-analysis examine factors associated with death from heatstroke
2. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
3. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
4. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
5. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
6. Physical Therapist Provides Injury Analysis for Fantasy Football
7. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
8. Meta-Analysis of Blood Phe Levels and Clinical Outcomes in PKU Published
9. OCS and Press Ganey Partner to Create Joint Analysis of Outcomes and Satisfaction
10. New Analysis Underscores Legality of Physician Ranking and Public Reporting Systems When Used by Health Insurers to Improve Health Care Quality
11. Barta joins Conseco as Senior Vice President, Financial Planning & Analysis; Barra named Senior Vice President, Internal Audit; Clarke to head Investor Relations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... 20, 2017 , ... ChenMed , a leading provider of value-based care ... Center as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of ... Officer of Ambulatory Services for the UVA Health System, brings 30 years of highly ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia ... that progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and ... and relapse. With such a challenging diagnosis that requires immediate action, patients ...
(Date:7/20/2017)... 20, 2017 (PRWEB) , ... ... ... a global provider of enterprise-grade IT operations analytics and application performance monitoring ... one of world’s largest healthcare services providers. , According to Peter Ohrenberger, ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... law firm headquartered in Houston, is pleased to announce their expansion to the ... affordable housing experience, directors Alysse Hollis and Ronald Bell, and of counsels, John ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... For individuals ... utmost importance. The adjustable beds used in such facilities are specially designed to accommodate ... adequate arm support. , An inventor from Rochester, Ind., has invented the patent-pending ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
(Date:7/11/2017)... 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... Administration (FDA) has agreed to schedule an End-of-Phase II ... trial of its oral insulin capsule ORMD-0801 in the ... met primary and secondary endpoints by indicating a statistically ...
(Date:7/10/2017)... 2017 Locus Biosciences Inc. today announced the ... development of CRISPR-Cas3 antimicrobial therapeutics. Financing for the round ... Internet services provider, and joined by the North Carolina ... product programs targeting antibiotic resistant infections and other microbiome-related ... Dr. Rodolphe Barrangou and Dr. Charles ...
Breaking Medicine Technology: